Ulcerative colitis, a chronic inflammatory condition of the colon, is far more than a digestive disorder. Clinicians have long observed that people with the disease experience anxiety at strikingly higher rates than the general population, yet the biological basis of this comorbidity has remained murky. A team led by Yaojiang Liu and Shengjie Huang of The Second Affiliated Hospital of Chongqing Medical University, together with colleagues and corresponding author Song He, set out to determine whether a specific molecular player in the gut lining could determine how vulnerable the brain becomes when the gut is inflamed.

The focus of their investigation was GPR35, a G-protein-coupled receptor expressed on intestinal epithelial cells. G-protein-coupled receptors are among the most druggable protein families in biology, sitting in cell membranes where they relay signals from the outside environment into the cell. GPR35 in particular has attracted attention because it can sense small metabolites produced by the body and by microbes, placing it at a natural crossroads between diet, bacteria, and host physiology. The researchers hypothesized that this receptor might serve as a gatekeeper for messages traveling along the microbiome-gut-brain axis, the bidirectional communication network linking gut microbes and their chemical products to brain function and behavior.

To test the idea, the team generated mice in which GPR35 was deleted specifically from intestinal epithelial cells while the rest of the animal remained genetically intact. These animals, known as GPR35ΔIEC mice, were then subjected to chemically induced colitis, a standard laboratory model that reproduces key features of ulcerative colitis, including inflammation of the colon and disruption of the gut lining. When the researchers compared the colitic knockout animals with colitic controls carrying normal GPR35, a clear behavioral difference emerged. The mice lacking the gut receptor showed markedly greater susceptibility to anxiety-like behaviors, spending less time exploring open, elevated spaces and less time in brightly lit zones, classic signs of heightened fearfulness in rodents.

Crucially, the anxiety was not explained by the severity of gut inflammation alone. Something beyond the inflamed colon was amplifying the behavioral response, and the trail led back to the gut’s microbial residents. Sequencing of the gut microbiota revealed that loss of epithelial GPR35 triggered a significant disturbance in the composition of the bacterial community. Among the casualties was Limosilactobacillus reuteri, a lactic acid-producing bacterium widely regarded as beneficial and frequently associated with gut and mental health. The abundance of L. reuteri dropped in the GPR35-deficient animals, and with it fell the levels of one of the bacterium’s signature metabolic products: indole-3-lactic acid, or ILA.

ILA belongs to a family of compounds derived from tryptophan, the amino acid best known as the precursor of serotonin. Gut bacteria convert dietary tryptophan into indole derivatives, including ILA, which can act as signaling molecules in the host. The Chongqing team found that when colitic mice lacking gut GPR35 received ILA, their anxiety-like behaviors eased. The molecule, in other words, was not merely a passive marker of a healthy microbiome but an active messenger capable of calming the anxious brain.

How could a bacterial metabolite produced in the gut lumen influence behavior? The answer, the researchers discovered, lies in the hippocampus, the brain region central to emotion regulation, learning, and the stress response. In anxious animals, the hippocampus showed signs of astrocyte activation. Astrocytes are star-shaped glial cells that support neurons and, when activated during inflammation, can release inflammatory mediators that disrupt normal neuronal function. ILA treatment suppressed this activation. The pathway the team traced runs through the aryl hydrocarbon receptor, or AhR, a transcription factor found in many cell types and a well-known sensor of microbial and dietary indoles. By engaging AhR and downstream interleukin-22 signaling, ILA restrained the inflammatory activation of hippocampal astrocytes, allowing the brain’s emotional circuitry to function more normally despite the ongoing disease.

The researchers then turned to humans to see whether the same signature exists in patients. They recruited individuals with ulcerative colitis, some of whom also suffered from comorbid anxiety, and analyzed their blood and gut tissue. The results were strikingly consistent with the animal data. Peripheral ILA concentrations were significantly lower in UC patients with anxiety than in those without, and the abundance of mucosa-associated L. reuteri, bacteria clinging to the gut lining rather than simply floating in the lumen, was similarly diminished. The convergence of the mouse and human findings strengthens the case that the GPR35-microbiome-ILA axis is not a laboratory artifact but a feature of human disease.

Taken together, the study sketches a coherent mechanistic chain. Gut epithelial GPR35 supports a healthy microbial community, including L. reuteri, which in turn produces ILA from tryptophan. ILA travels along the gut-brain axis, engages AhR-IL-22 signaling in the hippocampus, and restrains astrocyte activation there, protecting the brain from the anxiety-promoting effects of inflammation. Remove GPR35 from the picture, as the knockout mice demonstrate, and the entire cascade unravels: the microbiome becomes disturbed, ILA falls, astrocytes activate, and anxiety-like behavior intensifies. The receptor, in the authors’ framing, acts as an intermediate player and messenger along the gut-brain axis, quietly shaping how vulnerable the brain is to the inflammatory storm generated by colitis.

The implications are considerable. Because GPR35 is a cell-surface receptor, it is the kind of molecule that medicinal chemists know how to target, and agonists of GPR35 have already been explored in other contexts. The study suggests that boosting GPR35 signaling in the gut, restoring L. reuteri through probiotics, or supplementing ILA directly could each represent strategies to prevent or treat anxiety in ulcerative colitis patients. More broadly, the work adds to a growing body of evidence that metabolites derived from bacterial tryptophan metabolism are key chemical intermediaries between the gut and the brain, with consequences that extend from digestion to mood.

The authors caution that much remains to be worked out, including the precise cellular targets of ILA within the brain, whether the findings generalize to anxiety in other inflammatory conditions, and how such interventions might translate into safe and effective therapies. The research was conducted with appropriate ethical oversight, approved by the institutional review board of The Second Affiliated Hospital of Chongqing Medical University for the human study and by the laboratory animal welfare committee of Chongqing Medical University for the animal work, with informed consent obtained from all human participants. Still, with anxiety among inflammatory bowel disease patients remaining underdiagnosed and poorly treated, the identification of a gut-derived molecular switch that influences anxiety susceptibility offers a genuinely new target, one that sits at the intersection of gastroenterology, microbiology, and neuroscience. If the pathway holds up in further studies, the era of treating a psychiatric symptom with a molecule made by gut bacteria may be drawing closer.

The gut–brain axis describes the two-way communication network linking the gastrointestinal tract and the central nervous system. Signals travel through several routes, including the vagus nerve, immune molecules, hormones and metabolites produced when intestinal bacteria break down food. Because depression and anxiety involve changes in stress regulation, inflammation, metabolism and neural signaling, researchers have begun asking whether modifying the gut microbiome could complement established psychiatric treatments.

Probiotics are live microorganisms administered with the intention of providing a health benefit. In the context of mental health research, they are sometimes described as “psychobiotics,” although that term does not yet represent a clinically standardized category. Different bacterial strains can produce different compounds and interact with the intestinal lining in distinct ways. A multi-strain formulation is therefore designed to create broader biological effects than a single-strain product, although combining strains does not automatically guarantee that they will work better together.

The study focuses on adults experiencing depressive and anxiety symptoms and follows the intervention for 12 weeks. That duration is long enough to observe potential changes in symptom patterns, while remaining relatively brief compared with long-term psychiatric and microbiome research. As a pilot study, the work is primarily important for testing feasibility, identifying signals that justify larger trials and exploring how a probiotic intervention might be evaluated in people with clinically relevant emotional symptoms.

The biological theory behind the intervention is plausible but complex. Some intestinal bacteria can generate short-chain fatty acids, including acetate, propionate and butyrate, which influence immune activity, the intestinal barrier and cellular energy metabolism. Other microbial products may interact with tryptophan pathways, potentially affecting the availability of biochemical precursors involved in serotonin signaling. These mechanisms could theoretically influence brain function, but laboratory plausibility is not the same as demonstrated clinical effectiveness.

The microbiome may also interact with the body’s stress-response system. Depression and anxiety are frequently associated with altered activity of the hypothalamic–pituitary–adrenal axis, the hormonal network that helps the body respond to stress. Intestinal microbes can influence immune signaling and endocrine responses, while stress itself can alter gut motility, barrier function and microbial composition. This creates a feedback loop in which psychological distress and gastrointestinal biology may reinforce one another, making the direction of cause and effect difficult to establish.

That difficulty is central to interpreting probiotic research. The composition of the gut microbiome varies substantially between individuals and is influenced by diet, medication, sleep, age, geography and existing health conditions. Antibiotics and antidepressant medications can also affect microbial communities or gastrointestinal function. A probiotic that produces a measurable effect in one population may have a smaller or different effect in another, depending on the organisms already present and the host’s underlying biology.

The 12-week pilot should therefore be viewed as an exploratory contribution rather than definitive evidence that probiotics treat depression or anxiety. Pilot studies often involve limited participant numbers and may not be designed to detect modest differences with the statistical confidence required for clinical recommendations. They can nevertheless reveal whether participants are willing to follow the regimen, whether the intervention appears tolerable and whether symptom or biological changes are large enough to merit a controlled trial with more participants.

The study arrives at a moment when commercial interest in mental-health probiotics is moving faster than the evidence base. Products marketed for mood support are widely available, but supplements can differ in bacterial strains, doses, manufacturing quality and stability. A scientific trial evaluates a defined formulation under controlled conditions, whereas an over-the-counter product may not reproduce the same microbial combination or dosage. For patients, the distinction matters: probiotic research may eventually identify useful adjuncts, but it does not currently replace psychotherapy, prescribed medication or professional evaluation.

The broader significance of the work lies in its attempt to connect psychiatry with systems biology. Depression and anxiety are not single-pathway disorders, and the gut microbiome is not a simple switch that can be turned on or off. A multi-strain intervention offers one way to investigate whether coordinated changes in intestinal ecology can influence immune, metabolic and neural processes associated with emotional health. The findings from this pilot will need to be confirmed through larger, randomized and carefully controlled studies, but they add to a rapidly developing scientific conversation about how the microbes within the body may participate in the biology of the mind.

Subject of Research: Multi-strain probiotic intervention and its potential relationship to depressive and anxiety symptoms in adults.

Article Title: Multi-strain probiotic intervention in adults with depressive and anxiety symptoms: A 12-Week pilot study

Article References: Ovadia, Y.S., Okal, T., Gefel, D. et al. “Multi-strain probiotic intervention in adults with depressive and anxiety symptoms: A 12-Week pilot study.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04334-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04334-6

Keywords: probiotics, depression, anxiety, gut–brain axis, microbiome, psychobiotics, mental health, translational psychiatry

The authors emphasize that environmental exposures vary dramatically across regions—diet composition, sanitation infrastructure, urbanization patterns, early-life factors, and infection burden. These variables can shape microbiome development and function, which in turn can influence host pathways relevant to stress physiology and neuroinflammation. If studies are concentrated in HIC settings, the resulting models may overfit to microbial configurations and environmental contexts that are atypical elsewhere.

In their first argument, the researchers warn that overrepresentation of HIC cohorts could distort our understanding of how the axis operates in real-world mental health risk. For example, microbiome signatures associated with psychiatric outcomes might differ when baseline diets, commensal diversity, or pathogen-driven immune tone vary. The consequence is a partial, context-dependent theory—one that may not translate well to populations in low- and middle-income countries (LMICs).

Second, the paper highlights an opportunity often missed: LMICs may provide “natural experiments” where environmental forces differ in systematic ways. By comparing populations with distinct yet stable exposure profiles, researchers can disentangle which environmental drivers are most influential—whether through changes in fiber fermentation, microbial metabolite availability, or immune modulation.

Third, the authors argue that intervention pipelines could be limited if lifestyle-informed treatments are developed primarily from HIC-derived evidence. Microbiome-targeted approaches—such as diet-based strategies—may require adaptation to local food systems, cultural practices, and existing microbial ecosystems to be effective and equitable.

Importantly, the case is framed as scientific rigor rather than charity alone. Studying the microbiome–gut–brain axis across broader geographies can generate more generalizable mechanisms and better estimates of causal pathways.

The authors conclude that expanding research into the global south is therefore both ethically desirable and methodologically necessary, with the potential to produce mental health benefits that scale beyond the contexts where current evidence was generated.

Subject of Research: Microbiome–gut–brain axis and mental health across regions
Article Title: Global mental health benefits from expanding microbiome–gut–brain axis research to the global south
Article References: Valderrama, B., Morais, L.H., Lavelle, A. et al. Global mental health benefits from expanding microbiome–gut–brain axis research to the global south. Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00690-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s44220-026-00690-w
Keywords: microbiome–gut–brain axis; global mental health; LMICs; environmental exposures; mental health interventions